Sovran Advisors, LLC Summit Therapeutics Inc. Transaction History
Sovran Advisors, LLC
- $954 Billion
- Q2 2025
A detailed history of Sovran Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Sovran Advisors, LLC holds 150,047 shares of SMMT stock, worth $4.18 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
150,047
Previous 146,528
2.4%
Holding current value
$4.18 Million
Previous $3.61 Billion
4.34%
% of portfolio
0.36%
Previous 0.47%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
239Shares Held
88MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$681 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$325 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.61B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...